Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases
The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the ce...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Felder, Christian C. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes - March, Brayden ELSEVIER, 2023, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:136 ; year:2018 ; day:1 ; month:07 ; pages:449-458 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.neuropharm.2018.01.028 |
|---|
| Katalog-ID: |
ELV043722903 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV043722903 | ||
| 003 | DE-627 | ||
| 005 | 20230626004048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuropharm.2018.01.028 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000297A.pica |
| 035 | |a (DE-627)ELV043722903 | ||
| 035 | |a (ELSEVIER)S0028-3908(18)30028-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.88 |2 bkl | ||
| 100 | 1 | |a Felder, Christian C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. | ||
| 520 | |a The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. | ||
| 650 | 7 | |a Muscarinic |2 Elsevier | |
| 650 | 7 | |a M1 |2 Elsevier | |
| 650 | 7 | |a Neurodegenerative |2 Elsevier | |
| 650 | 7 | |a M4 |2 Elsevier | |
| 650 | 7 | |a Orthosteric |2 Elsevier | |
| 650 | 7 | |a Clinical |2 Elsevier | |
| 650 | 7 | |a Cognition |2 Elsevier | |
| 650 | 7 | |a Neuropsychiatric |2 Elsevier | |
| 650 | 7 | |a Alzheimer |2 Elsevier | |
| 650 | 7 | |a Allosteric |2 Elsevier | |
| 650 | 7 | |a Psychosis |2 Elsevier | |
| 650 | 7 | |a Neurology |2 Elsevier | |
| 650 | 7 | |a Receptor |2 Elsevier | |
| 650 | 7 | |a Acetylcholine |2 Elsevier | |
| 650 | 7 | |a Preclinical |2 Elsevier | |
| 700 | 1 | |a Goldsmith, Paul J. |4 oth | |
| 700 | 1 | |a Jackson, Kimberley |4 oth | |
| 700 | 1 | |a Sanger, Helen E. |4 oth | |
| 700 | 1 | |a Evans, David A. |4 oth | |
| 700 | 1 | |a Mogg, Adrian J. |4 oth | |
| 700 | 1 | |a Broad, Lisa M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a March, Brayden ELSEVIER |t Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes |d 2023 |g Amsterdam [u.a.] |w (DE-627)ELV009446303 |
| 773 | 1 | 8 | |g volume:136 |g year:2018 |g day:1 |g month:07 |g pages:449-458 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.neuropharm.2018.01.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.88 |j Urologie |j Nephrologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 136 |j 2018 |b 1 |c 0701 |h 449-458 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
c c f cc ccf |
|---|---|
| matchkey_str |
felderchristiancgoldsmithpauljjacksonkim:2018----:urnsauomsaiimad4eetradutresonu |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
44.88 |
| publishDate |
2018 |
| allfields |
10.1016/j.neuropharm.2018.01.028 doi GBV00000000000297A.pica (DE-627)ELV043722903 (ELSEVIER)S0028-3908(18)30028-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.88 bkl Felder, Christian C. verfasserin aut Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Elsevier Goldsmith, Paul J. oth Jackson, Kimberley oth Sanger, Helen E. oth Evans, David A. oth Mogg, Adrian J. oth Broad, Lisa M. oth Enthalten in Elsevier Science March, Brayden ELSEVIER Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes 2023 Amsterdam [u.a.] (DE-627)ELV009446303 volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 https://doi.org/10.1016/j.neuropharm.2018.01.028 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 136 2018 1 0701 449-458 10 045F 610 |
| spelling |
10.1016/j.neuropharm.2018.01.028 doi GBV00000000000297A.pica (DE-627)ELV043722903 (ELSEVIER)S0028-3908(18)30028-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.88 bkl Felder, Christian C. verfasserin aut Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Elsevier Goldsmith, Paul J. oth Jackson, Kimberley oth Sanger, Helen E. oth Evans, David A. oth Mogg, Adrian J. oth Broad, Lisa M. oth Enthalten in Elsevier Science March, Brayden ELSEVIER Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes 2023 Amsterdam [u.a.] (DE-627)ELV009446303 volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 https://doi.org/10.1016/j.neuropharm.2018.01.028 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 136 2018 1 0701 449-458 10 045F 610 |
| allfields_unstemmed |
10.1016/j.neuropharm.2018.01.028 doi GBV00000000000297A.pica (DE-627)ELV043722903 (ELSEVIER)S0028-3908(18)30028-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.88 bkl Felder, Christian C. verfasserin aut Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Elsevier Goldsmith, Paul J. oth Jackson, Kimberley oth Sanger, Helen E. oth Evans, David A. oth Mogg, Adrian J. oth Broad, Lisa M. oth Enthalten in Elsevier Science March, Brayden ELSEVIER Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes 2023 Amsterdam [u.a.] (DE-627)ELV009446303 volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 https://doi.org/10.1016/j.neuropharm.2018.01.028 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 136 2018 1 0701 449-458 10 045F 610 |
| allfieldsGer |
10.1016/j.neuropharm.2018.01.028 doi GBV00000000000297A.pica (DE-627)ELV043722903 (ELSEVIER)S0028-3908(18)30028-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.88 bkl Felder, Christian C. verfasserin aut Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Elsevier Goldsmith, Paul J. oth Jackson, Kimberley oth Sanger, Helen E. oth Evans, David A. oth Mogg, Adrian J. oth Broad, Lisa M. oth Enthalten in Elsevier Science March, Brayden ELSEVIER Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes 2023 Amsterdam [u.a.] (DE-627)ELV009446303 volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 https://doi.org/10.1016/j.neuropharm.2018.01.028 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 136 2018 1 0701 449-458 10 045F 610 |
| allfieldsSound |
10.1016/j.neuropharm.2018.01.028 doi GBV00000000000297A.pica (DE-627)ELV043722903 (ELSEVIER)S0028-3908(18)30028-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.88 bkl Felder, Christian C. verfasserin aut Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Elsevier Goldsmith, Paul J. oth Jackson, Kimberley oth Sanger, Helen E. oth Evans, David A. oth Mogg, Adrian J. oth Broad, Lisa M. oth Enthalten in Elsevier Science March, Brayden ELSEVIER Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes 2023 Amsterdam [u.a.] (DE-627)ELV009446303 volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 https://doi.org/10.1016/j.neuropharm.2018.01.028 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 136 2018 1 0701 449-458 10 045F 610 |
| language |
English |
| source |
Enthalten in Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes Amsterdam [u.a.] volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 |
| sourceStr |
Enthalten in Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes Amsterdam [u.a.] volume:136 year:2018 day:1 month:07 pages:449-458 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Urologie Nephrologie |
| institution |
findex.gbv.de |
| topic_facet |
Muscarinic M1 Neurodegenerative M4 Orthosteric Clinical Cognition Neuropsychiatric Alzheimer Allosteric Psychosis Neurology Receptor Acetylcholine Preclinical |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes |
| authorswithroles_txt_mv |
Felder, Christian C. @@aut@@ Goldsmith, Paul J. @@oth@@ Jackson, Kimberley @@oth@@ Sanger, Helen E. @@oth@@ Evans, David A. @@oth@@ Mogg, Adrian J. @@oth@@ Broad, Lisa M. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009446303 |
| dewey-sort |
3610 |
| id |
ELV043722903 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043722903</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626004048.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.neuropharm.2018.01.028</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000297A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043722903</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0028-3908(18)30028-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.88</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Felder, Christian C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Muscarinic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">M1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurodegenerative</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">M4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Orthosteric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognition</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuropsychiatric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alzheimer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allosteric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Psychosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Acetylcholine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Preclinical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goldsmith, Paul J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jackson, Kimberley</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanger, Helen E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Evans, David A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mogg, Adrian J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Broad, Lisa M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">March, Brayden ELSEVIER</subfield><subfield code="t">Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009446303</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:136</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:1</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:449-458</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.neuropharm.2018.01.028</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.88</subfield><subfield code="j">Urologie</subfield><subfield code="j">Nephrologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">136</subfield><subfield code="j">2018</subfield><subfield code="b">1</subfield><subfield code="c">0701</subfield><subfield code="h">449-458</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Felder, Christian C. |
| spellingShingle |
Felder, Christian C. ddc 610 bkl 44.88 Elsevier Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases |
| authorStr |
Felder, Christian C. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009446303 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.88 bkl Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical Elsevier |
| topic |
ddc 610 bkl 44.88 Elsevier Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical |
| topic_unstemmed |
ddc 610 bkl 44.88 Elsevier Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical |
| topic_browse |
ddc 610 bkl 44.88 Elsevier Muscarinic Elsevier M1 Elsevier Neurodegenerative Elsevier M4 Elsevier Orthosteric Elsevier Clinical Elsevier Cognition Elsevier Neuropsychiatric Elsevier Alzheimer Elsevier Allosteric Elsevier Psychosis Elsevier Neurology Elsevier Receptor Elsevier Acetylcholine Elsevier Preclinical |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p j g pj pjg k j kj h e s he hes d a e da dae a j m aj ajm l m b lm lmb |
| hierarchy_parent_title |
Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes |
| hierarchy_parent_id |
ELV009446303 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009446303 |
| title |
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases |
| ctrlnum |
(DE-627)ELV043722903 (ELSEVIER)S0028-3908(18)30028-5 |
| title_full |
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases |
| author_sort |
Felder, Christian C. |
| journal |
Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes |
| journalStr |
Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
449 |
| author_browse |
Felder, Christian C. |
| container_volume |
136 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 44.88 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Felder, Christian C. |
| doi_str_mv |
10.1016/j.neuropharm.2018.01.028 |
| dewey-full |
610 |
| title_sort |
current status of muscarinic m1 and m4 receptors as drug targets for neurodegenerative diseases |
| title_auth |
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases |
| abstract |
The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. |
| abstractGer |
The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. |
| abstract_unstemmed |
The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases |
| url |
https://doi.org/10.1016/j.neuropharm.2018.01.028 |
| remote_bool |
true |
| author2 |
Goldsmith, Paul J. Jackson, Kimberley Sanger, Helen E. Evans, David A. Mogg, Adrian J. Broad, Lisa M. |
| author2Str |
Goldsmith, Paul J. Jackson, Kimberley Sanger, Helen E. Evans, David A. Mogg, Adrian J. Broad, Lisa M. |
| ppnlink |
ELV009446303 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.neuropharm.2018.01.028 |
| up_date |
2024-07-06T19:34:43.473Z |
| _version_ |
1803859508304281600 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043722903</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626004048.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.neuropharm.2018.01.028</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000297A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043722903</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0028-3908(18)30028-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.88</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Felder, Christian C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic receptor M1 and M4 subtypes which are highly expressed in the central nervous system, in cortex, hippocampus and striatum, key areas of cognitive and neuropsychiatric control, have received particular attention. Historical muscarinic drug development yielded first generation agonists with modest selectivity for these two receptor targets over M2 and M3 receptors, the major peripheral sub-types hypothesised to underlie the dose-limiting clinical side effects. More recent compound screening and medicinal chemistry optimization of orthosteric and allosteric agonists, and positive allosteric modulators binding to sites distinct from the highly homologous acetylcholine binding pocket have yielded a collection of highly selective tool compounds for preclinical validation studies. Several M1 selective ligands have progressed to early clinical development and in time will hopefully lead to useful therapeutics for treating symptoms of Alzheimer's disease and related disorders.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Muscarinic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">M1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurodegenerative</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">M4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Orthosteric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognition</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuropsychiatric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alzheimer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allosteric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Psychosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Acetylcholine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Preclinical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goldsmith, Paul J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jackson, Kimberley</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanger, Helen E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Evans, David A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mogg, Adrian J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Broad, Lisa M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">March, Brayden ELSEVIER</subfield><subfield code="t">Phallus Preservation for Locally Advanced Proximal Primary Urethral Carcinoma: Technique and Outcomes</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009446303</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:136</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:1</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:449-458</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.neuropharm.2018.01.028</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.88</subfield><subfield code="j">Urologie</subfield><subfield code="j">Nephrologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">136</subfield><subfield code="j">2018</subfield><subfield code="b">1</subfield><subfield code="c">0701</subfield><subfield code="h">449-458</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3988676 |